ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mié, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
Los ingresos operativos se situaron en 314,6 millones de euros en el primer semestre de 2025, un descenso del 4% con respecto al mismo...
27 min
24/07/2025
Madrid, 10 de julio de 2025.- Laboratorios Farmacéuticos ROVI, S.A. (“ROVI” o la “Compañía”) informa que, con fecha de 9 de julio de 2025,...
5 min
10/07/2025
ROVI sigue adelante con su política de retribución al accionista tras completar el pasado año su tercer programa consecutivo de recompra...
7 min
18/06/2025
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.